Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist

Michael R. McKeown(Howard Hughes Medical Institute), Ravindra Majeti(Stanford University), Matthew G. Guenther(Arsenal Medical (United States)), Matthew L. Eaton(Lypro Biosciences (United States)), Christian Fritz(AVEO Oncology (United States)), Jakob Lovén(AVEO Oncology (United States)), Mei Wei Chen(AVEO Oncology (United States)), Steven M. Chan(Princess Margaret Cancer Centre), Chris Fiore(AVEO Oncology (United States)), Darren Smith(AVEO Oncology (United States)), Jeremy T. Lopez(AVEO Oncology (United States)), Julie L. Koenig(Stanford University), Kathryn Austgen(AVEO Oncology (United States)), Emily Lee(Environmental Law Institute), David A. Orlando(Arsenal Medical (United States)), M. Ryan Corces(Gladstone Institutes)
Cancer Discovery
July 20, 2017
Cited by 139


Related Papers